The half-life of Doxofylline is influenced by a number of known variables. It may be prolonged in patients with liver disease, in patients with congestive heart failure, in those affected with chronic obstructive lung disease or concomitant infections.
Use with caution in patients with hypertension, heart disease, hypoxemia, hyperthyroidism, chronic right ventricular failure, renal disease, in those with history of peptic ulcer, and in the elderly.
Frequently, patients with congestive heart failure have markedly prolonged drug plasma levels following discontinuation of the drug.
Doxofylline does not cause any risk of tolerance or addiction.
The safety and efficacy of Puroxan tablet is not established in children < 18 years old.